Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank
Outlook Therapeutics (Nasdaq: OTLK) announced it is unaffected by the Federal Deposit Insurance Corporation's control of Silicon Valley Bank (SVB), as it holds no deposits or investments at SVB.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Outlook Therapeutics (Nasdaq: OTLK) announced it is unaffected by the Federal Deposit Insurance Corporation's control of Silicon Valley Bank (SVB), as it holds no deposits or investments at SVB. The company focuses on developing ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab, targeting retinal diseases such as wet AMD, DME, and BRVO. The FDA has set a PDUFA goal date of August 29, 2023, for its BLA submission. Outlook Therapeutics partnered with AmerisourceBergen to enhance distribution and logistics services in anticipation of potential FDA approval.
Positive
- FDA has set a PDUFA goal date of August 29, 2023, for ONS-5010.
- Strategic partnership with AmerisourceBergen for enhanced distribution.
Negative
- None.
Details
News Market Reaction – OTLK
The recorded move for OTLK in the trading session of this news was +2.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ISELIN, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank (“SVB”).
Outlook Therapeutics does not hold any deposits or investments at SVB.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023. The submission is supported by Outlook Therapeutics’ wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. As part of the Company’s multi-year commercial planning process, and in anticipation of potential FDA approval in August 2023, Outlook Therapeutics and AmerisourceBergen have entered into a strategic commercialization agreement to expand the Company’s reach for connecting to retina specialists and their patients. AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services in the United States. For more information, please visit www.outlooktherapeutics.com.
CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.